secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axogen, Inc. (AXGN)
CIK:        0000805928
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0000805928-24-000107
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axogen Q2 revenue up 25.6% to $47.9M; net loss narrows; raises FY guidance
--------------------------------------------------------------------------

- Revenue $47.9M (+25.6% YoY); net loss $1.9M ($0.04/share) vs $6.7M loss prior year.
- Adjusted net income $2.0M ($0.05/share); adjusted EBITDA $5.6M vs loss $0.2M.
- FY2024 revenue guidance raised to $182-186M; gross margin guidance adjusted to 74-76%.
- Rolling BLA submission for Avance Nerve Graft initiated; expects completion Q3 2024, potential approval mid-2025.
- Launched Avive+ Soft Tissue Matrix in June; Core accounts up 18.7% to 412.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/805928/000080592824000107/0000805928-24-000107-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/805928/000080592824000107/axgn-20240808.htm
  HTML page:      https://secwatch.observer/filing/0000805928-24-000107

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer